Posted on

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

Loading

AUGUST, 02, 2022

AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of AlloHome™, a pan-organ patient monitoring solution that extends care into a patient’s home by capturing a range of vital health data that can help doctors with the early identification of adverse clinical events and the ability to make preemptive measures to avoid complications pre- and post-transplantation.
Read the full press release at CareDx.com.

Loading
Posted on

CareDx Demonstrates Industry-leading Commitment to Advancing Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 2022 American Society of Transplant Surgeons Symposium

Loading

JULY, 28, 2022

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation and top spot, for the third year in a row, as a Distinguished Founder’s Circle Sponsor for the 2022 American Society of Transplant Surgeons (ASTS) Summer Winter Symposium, taking place August 4-7, in Miami, Florida.
Read the complete press release at CareDx.com.

Loading
Posted on

CareDx Lead Sponsor for 2022 Donate Life Transplant Games

Loading

CareDx’s Mobile Health App, AlloCare, is the Official App for the Games

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jun. 28, 2022– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its participation and presenting sponsorship for the 2022 Donate Life Transplant Games taking place July 29 to August 3, 2022, in San Diego, California. CareDx’s transplant patient health app, AlloCare®, is the official app for the Games. Read the full press release here.

Loading
Posted on

CareDx The Transplant Company Releases Inaugural Environmental, Social and Governance Report

Loading

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jun. 21, 2022– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the release of its first environmental, social and governance (ESG) report.

“At CareDx, our mission and 100% dedication to improving the transplant ecosystem with innovative and intelligent solutions to improve patient outcomes shapes every aspect of our business and seamlessly integrates with an ESG framework,” said Reg Seeto, CareDx CEO and President. “As a leader in transplantation, we have a great responsibility to the transplant community, and using this framework is a natural step in our company’s evolution as we search for ways to continue to exemplify our values through actions which have a meaningful impact on our community, patients, and other stakeholder groups.” Read the full press release on CareDx.com here.

Loading
Posted on

CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk

Loading

Data from AiKidney Helps Clinicians Gain New Insights into Patient’s Risk of Allograft Rejection

CareDx to Host Investor Event to Share More Information About AiKidney, Clinical Pipeline and Using Augmented Information in Transplantation

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jun. 2, 2022– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it plans to expand its growing multimodality portfolio with AiKidney™, a new allograft risk assessment clinical decision support tool, in development, that includes AlloSure® and other transplant metrics.
Read the complete press release at CareDx.com.

Loading
Posted on

CareDx Innovation Showcased in Record-Breaking Number of Scientific Abstracts with Over 50 Presented at 2022 Transplant Congress

Loading

First Oral Presentation of OKRA Study Data Highlights CareDx Leadership in Multimodality KidneyCare

Symposium Highlights Power of CareDx Artificial Intelligence Solutions

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jun. 1, 2022– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2022 American Transplant Congress (ATC) with over 50 oral and scientific poster presentations. CareDx will also be sponsoring a symposium, three product theatres, and an Innovation Day session covering the latest innovations in transplantation.1 The ATC meeting takes place June 4-8 in Boston, Massachusetts. Read the full press release on CareDx.com.

Loading
Posted on

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation

Loading

CareDx Expands Transplant Portfolio in Europe

SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) —  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoietic cell transplantation (HCT).

“Transplantation is global and CareDx is proud to expand its leadership in Europe with CE marked AlloSeq HCT to help improve care for hematopoietic cell transplant patients,” said Reg Seeto, CEO and President of CareDx. “This new CE mark demonstrates our commitment to bringing high quality products to patients in Europe through our AlloSeq franchise, which includes a comprehensive suite of pre- and post-transplant solutions.”
Read the full press release on CareDx.com.

Loading
Posted on

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction

Loading

Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Giménez as the winner of the CareDx sponsored ISHLT Innovation Challenge Award.
Read the full press release on CareDx.com

Loading
Posted on

CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference

Loading

Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloSeq® portfolio of pre- and post-transplant solutions for human leukocyte antigen (HLA) typing, including QTYPE®, and post-transplant hematopoietic stem cell and organ transplant surveillance during poster presentations and the symposium taking place at this year’s EFI 2022 Conference. Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award

Loading

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Board member Hannah Valantine MD, a recognized leader in driving heart transplantation innovations and health equity, has received the 2022 Lifetime Achievement Award from the International Society for Heart and Lung Transplantation (ISHLT). Read the full press release on CareDx.com here.

Loading